

Clinical Research Newsletter

September 2026



CCDR Program Coordinator

Alaina Newsome underberga@sjchs.org



Georgia CORE

gancorp@georgiacore.org

Table of Contents

TOPIC	PAGE
Important Info	1
Research Base Meetings	2
URCC Annual Meeting - Staff Operations.	3
Research Base Roundup	4
NCORP Crossword Puzzle	5

Scientific Review Committee Overview

Purpose is to:

- Establish a forum where GA NCORP affiliates review and recommend NCI clinical trials for activation
- Ensure each trial offers:
 - scientific value
 - operational feasibility
- Alignment with NCI and network priorities
- Fit with the needs of the network population.
- Support a balanced clinical trial portfolio
- Increase accrual

GA NCORP SHARED EMAIL

To make it easier to connect with our team, we have established a dedicated GA NCORP inbox: gancorp@georgiacore.org

This inbox is available for all GA NCORP-related inquiries, including rostering requests, compliance and regulatory questions, policies and SOPs, education and training, monitoring and audit questions, and general program support. Your message will be routed to the appropriate team member, enabling us to respond more efficiently and ensure continuity of support.

Site Spotlight

Way to go sites, GA106 and GA031 for the most accruals last month! (Aug 1 – Aug 31)

Amendments

Addendum #7 to EAQ222CD, Effectiveness of Out- of-Pocket Cost COMMunication and Financial Navigation (CostCOM) in Cancer Patients.	Addendum #8 to EAQ221CD, Improving Medication Adherence in Breast Cancer using a CONnected CUStomized Treatment Platform (CONCURxP).
---	---

Important Dates



Halloween

Trick or Treat!



Election Day

Make a difference



Thanksgiving Break

Georgia CORE Closed

News

Have a topic, study or photo you'd like to share in next month's newsletter? Please share it with Kaylan Dixon (kdixon@georgiacore.org) to discuss adding it to the next edition of the GA NCORP Newsletter.

Clinical Research Newsletter

September 2026



Research Base Meetings

Upcoming Research Base Meetings*

Research Base	Date	Location
SWOG	October 9-11, 2026	Chicago, IL
	April 15-17, 2027	San Francisco, CA
	October 14-16, 2027	Chicago, IL
ECOG	October 20-22, 2026	Philadelphia, PA
	May 4-6, 2027	Baltimore, MD
	October 26-28, 2027	Chicago, IL
Wake Forest	October 12-14, 2026	Myrtle Beach, SC
NRG	January 28-30, 2027	Las Vegas, NV
	July 15-17, 2027	Washington, DC
UPCOMING ROUTINE AUDITS		
ECOG	TBD	Exact dates and method (onsite vs virtual) are pending.
NRG	TBD	
SWOG	TBD for 2027	
URCC	TBD for 2027	
Wake Forest	TBD for 2027	

*Please contact Shantoria Brown (sbrown@georgiacore.org) to discuss travel funds.

Members



GA NCORP representation at this year's URCC Annual Meeting. Left to Right: Alaina Newsome (LCRP), Tina Berry (Northside), Kaylan Dixon (Georgia CORE), Michelle Young (Northside), Sonia Hernandez (Northside), Katie Moore (Northside)

ECOG-ACRIN Fall Meeting

ECOG-ACRIN Fall 2026 Group Meeting is just weeks away, Tuesday, October 20, through Thursday, October 22, and we look forward to welcoming colleagues from across the country to Philadelphia for three days of scientific exchange, collaboration, and education. Whether you are an investigator, research advocate, or clinical research professional, the meeting offers valuable opportunities to connect with peers and stay informed about the latest developments.
[Register here](#)



2026 Wake Forest NCORP Research Base

2026 Wake Forest NCORP Research Base 13th Annual Meeting
October 12-14, 2026
Marriott Myrtle Beach Resort & Spa at Grande Dunes
Registration is Open!
Last day for meeting registration is 10/7/2026
[Register here](#)





Clinical Research Newsletter



September 2026

URCC Annual Meeting - Staff Operations

CONSENT

- Names must be fully redacted, except initials, which must remain visible. Initials and participant IDs should not be redacted.

RECONSENT

- Some amendments require reconsents of on-study participants. They must sign new consent form BEFORE completing any new study activities. Please be sure to upload new consent form to URCC with new assessment data. IC form in new studies. URCC to track more closely.
- Reconsent ASAP. If more than one reconsent is needed, participant only needs to sign the most recent version. Document!
- URCC has noted a number of missed reconsents, particularly on URCC-21038 (DiRECT). URCC will be tracking this more closely.

ELIGIBILITY

- Paper form is available on CTSU. Sites should use the eligibility form on CTSU rather than printing the protocol's eligibility section. Some protocols have e-signature options.

PAPER FORMS

- A wrong version used is a protocol deviation and has to be documented.
- All questions should be answered on forms, be sure to check when entering into REDCap to avoid missing fields that will be queried. The site should only enter what is on the paper that was completed by the participant.
- Forms should be completed in their entirety even if they don't appear relevant. If not relevant, select no/none/NA.

SOURCE DOCS

- Be sure to upload relevant medical records to the case summary.

DEMOGRAPHIC INFO

- Demographic info must come from the participant NOT the EMR. The participant will be asked in a later form and the information must match. Any mismatch info will result in a query for the coordinator to request registration correction from OPEN.

OPEN REGISTRATION

- Registration correction requests must come from the site, not URCC. The easiest option is to send an secure email to ctsuopenforms@westat.com. Must include study number, Participant ID and description of the correction needed.

ADVERSE EVENTS

- Use the chart as a guide, if it is not reportable, you will be asked to delete the info.
- Even though some protocols state, "All adverse events that in the opinion of the investigator are clinically significant will be documented and followed according to good clinical practices."

SAMPLE FORMS

- Since 10/21/24, DOB must be redacted on sample forms submitted by coordinators (e.g., Blood Req form).

SUBMITTING DATA

- Until Case Summary is marked "Complete" assessment data is not submitted. Don't mark Case Summary "Complete" until you're done entering data.

UPLOADING MISSING FORMS

- Upload to the Query Response, if too large to do this, upload to additional forms.

NEW QUERY SYSTEM

- Query Dashboard for easier retrieval of all open/unresolved queries – all queries will be in one place. Each query will be a single action item (no longer a list of issues) only one email per record. The second and third notices will be automated.



Clinical Research Newsletter

September 2026



Research Base Roundup



ECOG-ACRIN

EAQ171CD Smokefree Support Study 2.0 doubles quit rates. Published July 13 in the Journal of Clinical Oncology, this NCORP trial enrolled 306 newly diagnosed patients at 37 NCORP sites.

Six months of virtual telehealth counseling plus nicotine replacement therapy produced a 28.4% tobacco-free rate at six months versus 14.7% with Quitline referral alone. Participation was 81% versus 5%, medication adherence 83% versus 49.5%, and patient satisfaction 90% versus 40%.

AI-powered breast cancer recurrence test. A September 17 press release from the TAILORx research team describes a new AI-powered test offering more accurate prediction of breast cancer recurrence risk.

Earlier 2026 results. The ENDURANCE trial (NEJM, July 15) provided the first randomized evidence on optimal duration of lenalidomide maintenance in newly diagnosed multiple myeloma. Updated STAMP (EA6174) data on Merkel cell carcinoma were featured in The ASCO Post on July 9.

NRG

Four prostate cancer trials reached accrual goals. NRG-GU008 (INNOVATE), NRG-GU009 (PREDICT-RT), NRG-GU010 (GUIDANCE), and NRG-GU011 (PROMETHEAN) have all completed enrollment.

Perfect grant score and increased funding. NRG Oncology received a score of 10, the best possible, the maximum possible, on its six-year NCTN lead protocol organization renewal, marking the third consecutive cycle with the top score. The new grant cycle began March 1, 2026 and includes a modest funding increase over the 2019 to 2026 cycle.

Alliance

PAGODA (an Alliance CCCR trial): The Alliance would like to invite NCORP site responsible investigators, nurses, and clinical research professionals to participate in a regular All-Sites Call for A232402CD.

We encourage attendance from those who work with the oncology care team.

This Meeting will occur on Monday, September 28, 2026, at 12:00 PM CT (1:00 PM ET). The Zoom link below will be used for the call.

Currently participating institutions as well as interested institutions are invited to attend the site call. We look forward to your participation! To join the call, you will need to use the following Zoom link: [Join Zoom Meeting](#)

Wake Forest

Reminder. Current GCP certification is required for REDCap database access. Certificates can be uploaded to member profiles or emailed to NCORP@wakehealth.edu. Monthly site calls and office hours continue for WF2502CD STOP-VTE, WF-2401 STEPS-BC, WF-2501CD PGA, and WF2304-A172401-COSMIC.

WF-2502CD – STOP-VTE – Surgical Thromboprophylaxis Practice in Oncology Patients within the NCORP Network (STOP-VTE) is no longer onboarding sites for this study. Please continue to remind participants who are currently enrolled in Step 0 to complete their surveys as soon as possible; we are targeting September 30th for all surveys to be completed.

Complete the Crossword first, correctly to receive Georgia NCORP swag and a shout-out in the next issue! Send your responses to kdixon@georgiacore.org.



1					2														
												3			4				
	5																		
6																			
			7								8								
9																			
													10						
		11								12		13						14	
15																			
							16												
									17										
	18																		
		19																	
	20																		

ACROSS

1. Formal revision to a protocol that requires IRB approval before use
3. ___ documents, the original records where trial data is first captured
5. Report that confirms a cancer diagnosis from examined tissue
8. Emory's NCI-designated cancer institute in Atlanta
9. Cancer that starts in the epithelial cells lining organs and skin
12. Treatment that uses high-energy beams to destroy cancer cells
15. Health ___, a central focus of NCORP cancer care delivery research
17. Reviewer who verifies trial data against source records during site visits
18. Cancer that begins in the lymphocytes of the immune system
20. Expected course and likely outcome of a disease

DOWN

2. Skin cancer that arises in pigment-producing cells
4. Decrease or disappearance of the signs and symptoms of cancer
6. Gene that, when mutated, can drive uncontrolled cell growth
7. Federal institute that funds the NCORP program
10. Screening X-ray spotlighted during October's Breast Cancer Awareness Month
11. Data clarification request raised on a case report form
13. Any departure from the approved protocol, which must be documented and reported
14. Team member who guides patients past barriers to care and trial participation
16. Organization that initiates, manages, or funds a clinical trial
17. Rim of healthy tissue removed along with a tumor
19. Case report form, for short